Currently, about half of the U.S. COVID-19 vaccine stock is supplied by Moderna. Allowing the drugmaker to fit 14 doses into its vials could increase the country’s vaccine supply by as much as 20 percent.
The agency gave Moderna approval to make the switch so that the national COVID-19 vaccine supply can increase at a faster rate, but it asked the drugmaker to produce more data showing that storing 14 doses in each vial will not compromise the vaccine’s efficacy, according to the Times.
Reworking Moderna’s manufacturing operations to accommodate the switch could be done before the end of April, two anonymous sources familiar with the drugmaker’s production told the Times.
More articles on pharmacy:
Pharmacy chains on hiring sprees to support COVID-19 vaccination campaign
FDA authorizes new COVID-19 antibody cocktail from Eli Lilly
How retail pharmacies plan to handle leftover COVID-19 vaccine doses
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
